Studies how brain bleeds affect the brain and heart over time
Studies brain and heart injury in adults after bleeding in the brain.
Plain-language title generated from the registry record
Registry title: Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden bleed inside the skull, confirmed on a brain scan within 48 hours of the first symptoms. It studies how the bleed injures the brain and the heart.
- Age
- 18 Years to 80 Years
- Sex
- All sexes can join.
- Disease stage
- Acute bleeding inside the skull, confirmed by CT, MRI, CTA, MRA or DSA within 48 hours of symptom onset.
- Earlier treatment
- People cannot join if they had heart bypass surgery, a stent or another heart or blood-vessel procedure in the past 6 months. People cannot join if they had any surgery in the past 3 months.
Main reasons for not taking part
- Significant heart disease such as heart attack, heart failure or irregular heartbeat, unless stable and well controlled
- Brain tumour, stroke caused by a blocked vessel within 3 months, or earlier brain injury that could confuse the results
- Active cancer, or severe inflammatory or infectious disease
- Cannot give informed consent, and no legal representative can consent for them
- Any condition that the investigator considers unsafe or impractical for taking part
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06906432, who can take part
Where in China
- Beijing Tiantan Hospital Affiliated to Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT06906432
- Record updated
- 2 April 2025
- Original description
Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia, brain edema, and hydrocephalus. Complications such as cardiac injury may also arise, categorizing them within the cerebrocardiac syndrome (CCS). The clinical spectrum of CCS encompasses acute myocardial injury, acute coronary syndrome, left ventricular systolic and diastolic dysfunction, cardiac arrhythmias, and sudden cardiac death, all of which are associated with increased mortality and deterioration in patient status. The precise pathophysiological mechanisms underlying both cerebral and cardiac injuries remain enigmatic, and the implications for diagnosis and therapeutic strategies are yet to be fully explored.Read full original descriptionShow less
Multimodal Omics and Imaging Study on the Mechanisms of Brain-heart Injury in Patients With Intracranial Hemorrhage
Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia, brain edema, and hydrocephalus. Complications such as cardiac injury may also arise, categorizing them within the cerebrocardiac syndrome (CCS). The clinical spectrum of CCS encompasses acute myocardial injury, acute coronary syndrome, left ventricular systolic and diastolic dysfunction, cardiac arrhythmias, and sudden cardiac death, all of which are associated with increased mortality and deterioration in patient status. The precise pathophysiological mechanisms underlying both cerebral and cardiac injuries remain enigmatic, and the implications for diagnosis and therapeutic strategies are yet to be fully explored.
In this study, we propose to enroll patients with intracranial hemorrhage who will undergo conventional treatment and comprehensive multidisciplinary evaluations. Our observational research is grounded in a multimodal omics and imaging approach, aimed at investigating both local and systemic injuries subsequent to intracranial hemorrhage. This comprehensive strategy is intended to facilitate precise diagnosis, risk stratification, and clinical decision-making, while also shedding light on the pathophysiological mechanisms involved.
The primary objectives of this research are to address the following key questions:
* [Question 1] What are the pathophysiological mechanisms underlying cardiac injury in patients with intracranial hemorrhage? * [Question 2] What are the pathophysiological mechanisms responsible for early and delayed brain injuries following intracranial hemorrhage?\"
Inclusion: Patients aged 18 years or older at the time of enrollment; Acute intracranial hemorrhage confirmed by neuroimaging (CT, MRI，CTA, MRA, or DSA) within 48 hours of symptom onset; Ability to provide informed consent or have a legally authorized representative willing to consent on their behalf.
Exclusion: Patients with active brain tumors, ischemic stroke within 3 months or a history of previous brain injury that could confound the study findings; Patients with a history of significant cardiovascular disease, including myocardial infarction, heart failure, or arrhythmias, unless stable and well-controlled; Patients who have undergone cardiac bypass surgery, stent placement, or other cardiovascular interventions within the past 6 months; Patients with active malignant disease, severe inflammatory or infectious disease, or those who have undergone surgery for any reason within the past 3 months; Patients with any condition that, in the opinion of the investigator, would make it unsafe or impractical to participate in the study; Patients who refuse to participate in the study or cannot provide informed consent.